Highlights Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 05:00:50 2026-01-16 am EST			5-day change	1st Jan Change
1,175.55 ^INR	-0.92%		-2.80%	-7.51%

Jan. 16	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up Over 2% for Week	MT
Jan. 14	Dr. Reddy's Laboratories Ltd. Announces the Launch of Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%	CI

Highlights

Jan. 14	Dr. Reddy's Laboratories Ltd. Announces the Launch of Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%	CI
Dec. 17	Coya Therapeutics, Inc. Receives $4.2 Million Milestone Payment Under Development and License Agreement	CI
Dec. 16	Dr. Reddy's Laboratories Limited Announces USFDA Completed Inspection at Formulations Facility with Observations	CI
Dec. 09	Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als	CI
Dec. 08	Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary	MT
Dec. 08	Immutep SAS and Dr. Reddy?s Laboratories SA Enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa	CI
Dec. 08	Immutep enters into strategic collaboration with Dr. Reddy's	RE
Dec. 05	Sector Update: Health Care Stocks Lower Late Afternoon	MT
Dec. 05	Sector Update: Health Care Stocks Decline Friday Afternoon	MT
Dec. 05	European Equities Close Mixed in Friday Trading; EU GDP Grows 0.4% in Q3	MT
Dec. 05	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT
Dec. 05	Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide	MT
Dec. 04	Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide	MT
Nov. 24	Alvotech's Prolia, Xgeva Biosimilar Secures Approval in Europe	MT
Nov. 24	Alvotech Announces Approval of AVT03, a Biosimilar to Prolia®? and Xgeva®? in the European Economic Area	CI
Nov. 24	Dr. Reddy's Receives European Commission Approval for AVT03, A Proposed Biosimilar of Prolia and Xgeva	CI
Nov. 06	Esperion Q3 revenue up 69% on prescription volumes	RE
Nov. 05	Aurobindo Pharma's profit rises on steady domestic demand	RE
25-10-29	US FDA proposes moves to speed availability of some cheaper biotech medicines	RE
25-10-27	Dr. Reddy's Laboratories' Consolidated Profit Rises in Fiscal Q2	MT
25-10-24	Dr. Reddy's Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
25-10-24	India's Dr Reddy's misses profit view on stiff US competition for Revlimid generic	RE
25-10-24	India's Dr Reddy's misses quarterly profit view on stiff competition for cancer drug generic	RE
25-10-24	Dr. Reddy's Q2 consol net PAT at 13.47 billion rupees	RE
25-10-03	Esperion Therapeutics Settles Patent Lawsuit Against Dr. Reddy's Laboratories Over Cholesterol Drugs	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Dr. Reddy's Laboratories Ltd: Toripalimab drug launched in India

December 17, 2024 at 09:45 am EST